🔍

MEDICO - Medico Remedies

📊 NSE: MEDICO 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 9:45

📢 Recent Corporate Announcements

Medico Remedies Faces Rs 1.27 Lakh Penalty from NSE and BSE for Regulatory Non-Compliance

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 24 Feb 2026, 05:48 PM

Medico Remedies Limited has received notices from both NSE and BSE for alleged non-compliance with Regulation 6(1) of SEBI (LODR) Regulations. The exchanges have levied a penalty of Rs. 63,720 each, totaling approximately Rs. 1.27 lakh including GST. The company received these notices on February 20, 2026, and has subsequently filed waiver applications with both exchanges on February 24, 2026. Management states there is no material impact on the company's financial or operational activities due to this development.

NSE and BSE levied a penalty of Rs. 63,720 each (including GST) for Regulation 6(1) non-compliance.
The total financial penalty involved is approximately Rs. 1.27 lakh.
Notices were received on February 20, 2026, and waiver applications were filed on February 24, 2026.
The company states there is no material impact on financials, operations, or other activities.

💡 This is a minor regulatory matter with negligible financial impact; no immediate action is required from investors. However, it is advisable to monitor for any recurring compliance issues that might suggest internal governance weaknesses.

Medico Remedies Appoints Vidhi Ankit Shah as Company Secretary and Compliance Officer

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 18 Feb 2026, 04:14 PM

Medico Remedies Limited has officially appointed Ms. Vidhi Ankit Shah as the Company Secretary and Compliance Officer, effective February 18, 2026. This appointment fills a Key Managerial Personnel (KMP) position as required under Section 203 of the Companies Act, 2013. Ms. Shah brings over 9 years of professional experience in handling secretarial compliances for both listed and unlisted companies. The board approved this move following the recommendation of the Nomination and Remuneration Committee to ensure continued regulatory adherence.

Appointment of Ms. Vidhi Ankit Shah as Company Secretary and Compliance Officer effective Feb 18, 2026
Appointee possesses over 9 years of experience in secretarial and regulatory compliance functions
Designated as Key Managerial Personnel (KMP) under Section 203 of the Companies Act, 2013
The decision was finalized during the Board Meeting held on February 18, 2026

💡 This is a routine administrative appointment to ensure regulatory compliance and does not impact the company's fundamental value. No immediate action is required from investors.

Medico Remedies Approves Unaudited Financial Results for Q3 FY26

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 12 Feb 2026, 06:00 PM

Medico Remedies Limited held a board meeting on February 12, 2026, to approve the unaudited standalone financial results for the quarter and period ended December 31, 2025. The meeting was conducted efficiently, lasting only 30 minutes from 5:00 PM to 5:30 PM. The board also reviewed and approved the Auditors' Limited Review Report for the same period. This filing marks the completion of the company's regulatory requirements for the third quarter of the 2025-26 fiscal year.

Board approved Unaudited Standalone Financial Results for the quarter ended December 31, 2025.
The meeting was held on February 12, 2026, and concluded within 30 minutes.
Auditors' Limited Review Report was formally considered and approved by the board.
Compliance confirmed under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements.

💡 Investors should examine the detailed financial tables to evaluate revenue growth and margin performance compared to previous quarters. Monitor the stock for any price movement following the formal release of these earnings figures.

Medico Remedies Approves Unaudited Financial Results for Quarter Ended Dec 31, 2025

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 12 Feb 2026, 05:47 PM

Medico Remedies Limited has officially approved its unaudited standalone financial results for the quarter ended December 31, 2025. The board meeting was held on February 12, 2026, and concluded within 30 minutes, signifying a routine regulatory approval process. While the specific financial figures were not detailed in the summary letter, the announcement confirms the completion of the limited review by auditors. Investors should now look to the detailed financial tables for specific revenue and margin performance.

Board approved unaudited standalone financial results for the quarter ended December 31, 2025.
The board meeting was conducted on February 12, 2026, from 5:00 P.M. to 5:30 P.M.
The results were submitted along with the Auditors’ Limited Review Report as per SEBI regulations.
The filing covers the performance for the third quarter of the 2025-26 fiscal year.

💡 Investors should examine the full financial statements for specific growth in net profit and revenue. Compare the Q3 performance against previous quarters to assess the company's operational trajectory.

Medico Remedies Bags ₹37.18 Crore Order from UP Medical Supplies Corporation

🟢 POSITIVE ⭐ 7/10

ROUTINE 📅 27 Jan 2026, 11:52 AM

Medico Remedies Limited has secured a significant domestic supply order worth approximately ₹37.18 crore from the Uttar Pradesh Medical Supplies Corporation Limited. The contract involves the supply of multiple drugs to the Government of Uttar Pradesh's centralized distribution entity. The company is expected to complete the full supply of the order by October 31, 2026. This government contract provides strong revenue visibility for the company over the next 20 months.

Total order value is ₹37,17,62,439 (approximately ₹37.18 crore)
Contract awarded by Uttar Pradesh Medical Supplies Corporation Limited, a GoUP entity
The order involves the supply of multiple drugs for state-wide distribution
Project completion timeline is set for October 31, 2026

💡 Investors should view this as a positive development for revenue growth and monitor the company's ability to maintain margins on government-tendered contracts. Watch for timely execution updates as the October 2026 deadline approaches.

Medico Remedies Secures ₹73.23 Crore Order from UP Medical Supplies Corp

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 20 Jan 2026, 12:39 PM

Medico Remedies Limited has bagged a significant domestic order worth ₹73.23 crore from the Uttar Pradesh Medical Supplies Corporation Limited, a Government of Uttar Pradesh entity. The contract involves the supply of Azithromycin 500mg tablets across the state's healthcare network. The company is mandated to complete the full supply of the order by October 31, 2026. This large-scale government contract provides strong revenue visibility and validates the company's standing in the pharmaceutical supply chain.

Total order value is approximately ₹73,23,16,646 for drug supplies
Contract involves the supply of Azithromycin 500mg tablets to the UP Government
The execution timeline for the full order is set until October 31, 2026
The order is awarded by a domestic government entity with no promoter interest involved

💡 Investors should view this as a positive development for the company's order book and revenue growth. Monitor the company's ability to maintain margins while executing this large-scale government contract.

Medico Remedies to Close Trading Window from Jan 1, 2026 for Q3 FY26 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 30 Dec 2025, 05:31 PM

Medico Remedies Limited has announced the closure of its trading window starting January 1, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations. This closure is ahead of the declaration of the company's unaudited financial results for the quarter ending December 31, 2025. The restriction applies to all insiders, designated persons, and their immediate relatives to prevent any potential insider trading. The window will remain closed until 48 hours after the financial results are officially announced to the exchanges.

Trading window closure begins on January 1, 2026.
Closure is in relation to the Unaudited Financial Results for the quarter ended December 31, 2025.
Restriction applies to all Insiders, Designated Persons, and their immediate relatives.
The window will reopen 48 hours after the declaration of the quarterly results.

💡 This is a routine regulatory filing with no direct impact on the company's fundamentals. Investors should focus on the upcoming quarterly earnings release to evaluate the company's financial performance.

View All MEDICO Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company operates as a single operating segment (pharmaceutical formulations). Total revenue grew by 6.2% from INR 145 crore in FY2023-24 to INR 154 crore in FY2024-25. Revenue for the half-year ended September 30, 2025, reached INR 90.03 crore compared to INR 73.94 crore in the previous year's corresponding period, representing a 21.7% increase.

Geographic Revenue Split

The company is heavily export-oriented, with more than 95% of revenue generated from international markets. For the quarter ended September 30, 2025, international sales were INR 46.75 crore (89.6% of quarterly revenue) while domestic sales were INR 5.43 crore (10.4% of quarterly revenue). Key markets include Honduras, Dominican Republic, Nigeria, and the Philippines.

Profitability Margins

Operating Profit Margin improved from 8% in FY2023-24 to 9% in FY2024-25. Net Profit Margin increased from 6% to 7% in the same period. For the half-year ended September 30, 2025, the company reported a net profit of INR 4.39 crore, a 39.8% increase from INR 3.14 crore in the previous year's half-year period.

EBITDA Margin

EBITDA margin was reported at 7% in Q2 FY2024 and 8% in Q1 FY2024. Historical EBITDA margins have fluctuated between 4.7% and 11.5% over the last four fiscals due to raw material price volatility and forex fluctuations.

Capital Expenditure

The company has invested in a new manufacturing unit for ointments and creams. Capital work-in-progress (CWIP) stood at INR 0.47 crore as of September 30, 2025, compared to INR 0.36 crore as of March 31, 2025. Construction has also commenced on a new factory for beta-lactam tablets, capsules, dry syrups, and injections to scale operations.

Credit Rating & Borrowing

CRISIL Ratings maintains a 'Stable' outlook. The company exhibits a comfortable capital structure with a gearing ratio of 0.2 times and a total outside liabilities to adjusted networth (TOL/ANW) ratio of 0.9 times as of March 31, 2025. Interest coverage ratio is healthy at 20.35 times for FY2024-25.

⚙️ Operational Drivers

Raw Materials

Specific chemical names are not disclosed, but raw materials represent a significant cost component, with 15-20% of requirements being imported. Fluctuations in these costs directly impact the operating margins, which have historically ranged from 4.7% to 9.5%.

Import Sources

The company imports 15-20% of its raw materials. While specific countries are not listed, the management notes a strategy to de-risk dependency on China for key raw materials in line with industry trends.

Capacity Expansion

Current operations involve a diversified portfolio of 300 products. Expansion includes a new manufacturing unit for ointments and creams and a planned facility for beta-lactam products (Amoxicillin with potassium clavulanate) to drive future turnover growth.

Raw Material Costs

Raw material costs are susceptible to high volatility. While the company attempts to pass on price increases to customers, there is typically a time lag that affects short-term profitability.

Manufacturing Efficiency

The company is transitioning to more efficient manufacturing approaches and new technologies to remain competitive in pharmerging markets.

Logistics & Distribution

Distribution is primarily focused on exports (>95%), making the company highly sensitive to global shipping costs and international trade regulations.

📈 Strategic Growth

Expected Growth Rate

11%

Growth Strategy

Growth will be achieved through the production of an additional range of products, specifically Amoxicillin with potassium clavulanate tablets and dry syrups. The company is also expanding its manufacturing footprint with a new beta-lactam facility and targeting 'untouched' sectors in international markets to leverage the 3-6% projected global market CAGR.

Products & Services

Pharmaceutical formulations including anti-biotics, anti-infectives, antipyretics, analgesics, anti-diabetics, diuretics, antimalarials, NSAIDS, antiretrovirals, anti-ulcer drugs, antacids, and external preparations like creams and ointments.

New Products/Services

New product launches include Amoxicillin with potassium clavulanate tablets and dry syrups, which are expected to provide substantial growth in sales turnover and profitability.

Market Expansion

Targeting expansion in pharmerging markets and increasing penetration in existing regions like Honduras, Nigeria, and the Philippines.

🌍 External Factors

Industry Trends

The industry is shifting toward speciality products in developed markets and volume growth in pharmerging markets. There is a global trend of de-risking supply chains away from China for active pharmaceutical ingredients (APIs).

Competitive Landscape

Competes with both large-scale Indian pharmaceutical companies and local players in export markets. Scale is currently 'moderate,' which limits bargaining power.

Competitive Moat

The company's moat is built on the promoters' 40+ years of experience and a diversified portfolio of 300+ products. This prevents over-reliance on any single drug (no product >10% of sales), though it lacks the scale of major competitors.

Macro Economic Sensitivity

Highly sensitive to global healthcare spending and per capita income in pharmerging markets. The Indian pharma industry is expected to grow 6-8% YoY in FY25.

Consumer Behavior

Increasing healthcare awareness and an aging global population are driving higher demand for chronic and acute therapeutic medicines.

Geopolitical Risks

Trade barriers or regulatory changes in key export markets (Nigeria, Philippines, etc.) could disrupt 95% of the revenue stream.

⚖️ Regulatory & Governance

Industry Regulations

Operations must comply with WHO-GMP standards for manufacturing and IND AS for financial reporting. The company is subject to various drug control regulations in every country it exports to.

Taxation Policy Impact

The company provided for INR 1.31 crore in tax expenses for the half-year ended September 30, 2025, on a profit before tax of INR 5.91 crore (effective tax rate of approximately 22.2%).

⚠️ Risk Analysis

Key Uncertainties

Volatility in raw material prices and foreign exchange rates are the primary uncertainties, potentially impacting operating margins by 2-4% based on historical volatility ranges.

Geographic Concentration Risk

Extremely high geographic concentration in exports, with 95% of revenue coming from outside India.

Third Party Dependencies

Dependency on external suppliers for 15-20% of raw materials via imports and a growing dependency on the top 5 customers who now control 56% of revenue.

Technology Obsolescence Risk

The company identifies dependency on telecommunication and information technology systems as a risk factor in its caution statement.

Credit & Counterparty Risk

Gross Current Asset (GCA) days are high at 170-180 days, indicating a long wait time for receivables and potential credit risk if export customers delay payments.